Likewise, a combination of mibefradil (a blocker of CaV3 subfamily) and carboplatin synergistically inhibited the growth of platinum-resistant ovarian cancer cell lines A2780Cis and IGROV-1, suggesting that a combinatorial drug therapy using CaV inhibitors and conventional chemotherapeutics may serve as an effective treatment for ovarian cancer [133]. Here, CAV2 is linked to ovarian carcinoma.